Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcription factor c-Maf is extensively involved in the pathophysiology of multiple myeloma (MM), a fatal malignancy of plasma cells. In the present study, affinity chromatography and mass spectrometry were used to identify c-Maf ubiquitination-associated proteins, from which the E3 ligase
HERC4
was found to interact with c-Maf and catalyzed its polyubiquitination and subsequent proteasome-mediated degradation.
HERC4
mediated polyubiquitination at K85 and K297 in c-Maf, and this polyubiquitination could be prevented by the isopeptidase USP5. Further analysis on the NCI-60 cell line collection revealed that RPMI 8226, a MM-derived cell line, expressed the lowest level of
HERC4
. Primary bone marrow analysis revealed
HERC4
expression was high in normal bone marrow, but was steadily decreased during myelomagenesis. These findings suggested
HERC4
played an important role in MM progression. Moreover, ectopic
HERC4
expression decreased MM proliferation in vitro, and delayed xenograft
tumor growth
in vivo. Therefore, modulation of c-Maf ubiquitination by targeting
HERC4
may represent a new therapeutic modality for MM.
...
PMID:The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. 2682 10
The E3 ligase
HERC4
is overexpressed in human breast cancer and its expression levels correlated with the prognosis of breast cancer patients. However, the roles of
HERC4
in mammary tumorigenesis remain unclear. Here we demonstrate that the knockdown of
HERC4
in human breast cancer cells dramatically suppressed their proliferation, survival, migration, and
tumor growth
in vivo, while the overexpression of
HERC4
promoted their aggressive tumorigenic activities.
HERC4
is a new E3 ligase for the tumor suppressor LATS1 and destabilizes LATS1 by promoting the ubiquitination of LATS1. miRNA-136-5p and miRNA-1285-5p, expression of which is decreased in human breast cancers and is inversely correlated with the prognosis of breast cancer patients, are directly involved in suppressing the expression of
HERC4
. In summary, we discover a miRNA-
HERC4
-LATS1 pathway that plays important roles in the pathogenesis of breast cancer and represents new therapeutic targets for human breast cancer.
...
PMID:A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1. 3071 Mar 19